Rheumatology Advance Practice Providers (RhAPP)’s Post

Our experience of clinical iPSC lines showing differntiation into NK cells. More information including live imaging of human iNK cells engulfing K562 cells, availabe through below link!

Mechanism of action of antibody-drug conjugate. Read our summary and interview with the researchers 👉 https://bit.ly/3QYcnNn

New #ESMOGuideline #CLL. In essence, Modern Fix Treatment Duration Venetoclax based therapies are the treatment paradigm for CLL patients.

The recent study by He et al. (2024) explores the therapeutic potential of UC-MSCs and their extracellular vesicles (EVs) for treating chemotherapy-induced premature ovarian failure (POF). Administering UC-MSCs or EVs on day 6 after chemotherapy significantly improves ovarian function by promoting follicle growth, enhancing granulosa cell proliferation, and inhibiting apoptosis. EVs derived from UC-MSCs activate the PI3K/AKT pathway, with clusterin (CLU) playing a key role in reducing apoptosis. This study highlights a new molecular mechanism for UC-MSCs in POF treatment, offering a promising cell-free therapeutic approach to restore ovarian function. Read more: https://lnkd.in/gYKVsc8W #ovarianfailue #stemcelltherapy #stemcells #newstudies #umbilicalcordstemcells #mesenchymalstemcells

Two arms, one mission: multitasking for better treatment. That’s the essence of HMB-001, a bispecific antibody designed to restore the formation of a stable fibrin-platelet mesh. By binding to endogenous Factor VIIa with one arm of the bispecific antibody and targeting activated platelets via the TLT-1 receptor with the other arm, HMB-001 is driving localized thrombin generation and fostering fibrin formation where it matters most—in real-time, at the site of platelet activation. Prafull S. Gandhi, the brilliant scientist behind HMB-001, recently presented this novel mechanism of action at ACIPR. The oral presentation shared exciting pre-clinical data and first-in-human results from our Phase 1 study in individuals with Glanzmann Thrombasthenia (GT). This is just the beginning of HMB-001’s journey. A huge thanks to SETH/ISTH for organizing ACIPR. It was inspiring to witness all the cutting-edge research in GT and inherited platelet disorders. We’re now actively enrolling participants in our Phase 2 study in GT. Contact clinicaltrials@hemab.com and learn more at https://lnkd.in/ep3zSGdP #GlanzmannThrombasthenia #HMB001

In this Healio Video Perspective from the #ARVO2024 meeting, Allen C. Ho, MD, FASRS, discusses 12-month data on MCO-010 optogenetic therapy for patients with retinitis pigmentosa. https://lnkd.in/gkXwrqHx

This is a great webinar about humanized HLA. Biocytogen has the most powerful platform with humanization of Antibody repertoire, TCR repertoire and Antigen presentation systems! Please stay until the last question 🤪

Multiplex your CAR T cell-mediated cytotoxicity and cytokine release assays. If you are at #AACR2024 today, visit Sierra Barnes’ poster #4017 (Section 2, Board 26) to learn more. Abstract Title: CAR T cell-mediated cytotoxicity and cytokine release in response to varying levels of antigen expression on target cells #AACR24 #CancerResearch #CellTherapy #CARTcell #AxionBio Viswanath Lanka, David Greenberg, Steven Book, Rachel Osby, Julien Bradley

What drives our shared mission and values in the oncology community? It’s our dedication to innovation, compassion, and equity, synergized by the power of collaboration across all sectors. Each of us—from patients, to researchers, advocates, and educators—plays a role in overcoming barriers to better cancer care and survivorship. The American Lung Association’s BEAT Lung Cancer campaign is making strides in promoting biomarker testing education and advocacy, a critical tool for personalizing cancer treatment. Many patients, especially those in underserved communities, still lack access to these tests, which can determine the most effective treatment options for them. At Friends, our role as a science policy and advocacy organization is to complement these efforts by generating scientific evidence to inform policy through initiatives such as our biomarker diagnostics portfolio. Improved understanding of human biology has led to safer, more effective treatments via biomarker identification, but the variability in test results can hinder optimal patient care. By aligning diagnostic tests, we aim to overcome these challenges and ensure all patients with #cancer benefit from #precisionmedicine with consistent and reliable #biomarker testing. #WLCD24 #WorldLungCancerDay 🫁 Learn about ALA’s BEAT Lung Cancer campaign: https://lnkd.in/gfxYi89J 🧬 Learn about Friends’ Diagnostics Portfolio: https://lnkd.in/e9gacTVi https://lnkd.in/gS4PCYzG

Genome-wide association study of accessory pathways identifies coding variants in CCDC141 and SCN10A. Further research into CCDC141 could provide insights for anti-arrhythmic therapeutic targeting in the presence of an AP. https://ja.ma/4gfILX0